Background: The exact characteristics of primary ovarian carcinoid tumors remain largely unknown because of the rarity of the cases. This study aimed to investigate the clinical features, pathological characteristics, and therapeutic outcomes of patients with primary ovarian carcinoid tumors.
Methods: This retrospective case series included patients with primary ovarian carcinoid tumors diagnosed between January 2009 and December 2023 at the First Affiliated Hospital of Wenzhou Medical University.
Results: Fifteen patients were included. They were 45.8 ± 2.7 years at diagnosis. Eight tumors were located in the left ovary, while seven were in the right. All patients were stage I. Microscopically, nine tumors were classified as strumal carcinoid, two as insular carcinoid, three as trabecular carcinoid, and one as mixed. Synaptophysin (Syn) was positive in 14 cases, chromogranin A (CgA) in 10, CD56 in eight, thyroid transcription factor 1 (TTF-1) in five, and thyroglobulin (TG) in six. Twelve patients had a Ki67 index ≤ 7%. All 15 patients underwent surgery, with eight retaining fertility. Among them, one patient underwent comprehensive staging surgery, four underwent lateral adnexectomy, and three underwent cyst stripping. Seven patients underwent total hysterectomy and bilateral adnexectomy, including two patients undergoing comprehensive staging surgery. Three patients received intravenous chemotherapy. One patient was lost to follow-up. The remaining patients were followed up for 48-148 months; they were without recurrences and alive at the last follow-up.
Conclusions: Primary ovarian carcinoid tumors present with atypical symptoms and signs. Surgical intervention may be an optimal choice for treatment, leading to favorable prognostic outcomes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1186/s12957-025-03731-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluation of Laboratory-Derived Immunohistochemical Assays for Folate Receptor α Expression in Epithelial Ovarian Cancer and Comparison With a Companion Diagnostic.
Arch Pathol Lab Med
March 2025
From Translational Medicine, ImmunoGen, Inc, Waltham, Massachusetts (Deutschman, Sloss).
Context.—: The VENTANA FOLR1 (FOLR1-2.1) RxDx (FOLR1 CDx) assay, developed by Roche Tissue Diagnostics, is a Food and Drug Administration-approved immunohistochemical assay intended for use in the assessment of folate receptor α (FRα) expression in formalin-fixed, paraffin-embedded epithelial ovarian, fallopian tube, and primary peritoneal tumor specimens.
View Article and Find Full Text PDFThe contribution of coding variants to the heritability of multiple cancer types using UK Biobank whole-exome sequencing data.
Am J Hum Genet
March 2025
Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK; Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK.
Genome-wide association studies have been highly successful at identifying common variants associated with cancer; however, they do not explain all the inherited risks of cancer. Family-based studies, targeted sequencing, and, more recently, exome-wide association studies have identified rare coding variants in some genes associated with cancer risk, but the overall contribution of these variants to the heritability of cancer is less clear. Here, we describe a method to estimate the genome-wide contribution of rare coding variants to heritability that fits models to the burden effect sizes using an empirical Bayesian approach.
View Article and Find Full Text PDFEstablishment and Its Utility of a Patient-Derived Cell Xenografts (PDCX) Model with Cryopreserved Cancer Cells from Human Tumor.
Cells
February 2025
Department of Pathology, CHA Bundang Medical Center, CHA University, Seongnam-si 13496, Republic of Korea.
Patient-derived xenograft (PDX) models are powerful tools in cancer research, offering an accurate platform for evaluating cancer treatment efficacy and predicting responsiveness. However, these models necessitate surgical techniques for tumor tissue transplantation and face challenges with non-uniform tumor growth among animals. To address these issues, we attempted to develop a new PDX modeling method using high-grade serous ovarian cancer (HGSC), a fatal disease with a 5-year survival rate of 29%, which requires personalized research due to its morphological, genetic, and molecular heterogeneities.
View Article and Find Full Text PDFExamining the Outcomes of Palliative Oophorectomy of Ovarian Metastases in de-Novo Metastatic Colorectal Cancer and Its Association with RAS Mutation Status: Insights from a Single-Institution Perspective.
Cancer Manag Res
March 2025
Department of internal medicine, King Hussein Cancer Center, Amman, Jordan.
Background And Aim: Ovarian metastasis occurs in 3-5% of patients with CRC. Ovaries are considered sanctuary sites and typically do not respond effectively to chemotherapy. Patients with KRAS mutation generally have a worse prognosis compared to those with KRAS wild type.
View Article and Find Full Text PDFPlasma Cell-Rich Lymphoid Neoplasm in an Endocervical Polyp of the Uterine Cervix in a Perimenopausal 52-Year-Old Woman.
HCA Healthc J Med
February 2025
St David's North Austin Medical Center, Austin, Texas.
Background: The adaptive immune system consists of T and B lymphocytes, with some B lymphocytes further differentiating into plasma cells that secrete antibodies and make up the humoral immune system. Extramedullary plasmacytoma, mucosa-associated lymphoid tissue (MALT) lymphoma, and plasmablastic lymphoma are all plasma cell-rich lymphoid neoplasms that rarely present in the female genital tract. To date, few case reports of these malignancies arising within the uterine cervix exist.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!